SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

By afschroeder • July 30, 2025

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang W, Galsky MD. SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Future Oncol. 2025 Jul 29:1-8. doi: 10.1080/14796694.2025.2535280. Epub ahead of print. PMID: 40728126.

Tags: antibody-drug conjugate, disitamab vedotin, Hematology/Oncology, HER2, metastatic, PD-1, pembrolizumab, Publications, urothelial cancer

Related Posts

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T,[...]

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Cho SB, Hsu CH, Huang[...]

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of[...]